Overall market sentiment has been high on Cogent Biosciences Inc (COGT) stock lately. COGT receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
Cogent Biosciences Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on COGT!
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With COGT Stock Today?
Cogent Biosciences Inc (COGT) stock has fallen -0.45% while the S&P 500 has gained 0.07% as of 10:03 AM on Monday, Apr 1. COGT is lower by -$0.03 from the previous closing price of $6.72 on volume of 190,073 shares. Over the past year the S&P 500 is up 27.49% while COGT is lower by -37.77%. COGT lost -$2.42 per share in the over the last 12 months.
More About Cogent Biosciences Inc
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
Click Here to get the full Stock Report for Cogent Biosciences Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
